--- title: "Cookson Peirce & Co. Inc. Invests $975,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)" type: "News" locale: "en" url: "https://longbridge.com/en/news/230806508.md" description: "Cookson Peirce & Co. Inc. has invested $975,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by acquiring 11,670 shares in the fourth quarter. Other institutional investors have also increased their stakes in ITCI, with TimesSquare Capital Management raising its holdings by 91.8%. Intra-Cellular Therapies has a market cap of $13.95 billion and reported a quarterly revenue of $199.22 million, missing expectations. Analysts have mixed ratings on the stock, with an average rating of \"Hold\" and a consensus price target of $106.08." datetime: "2025-03-06T10:05:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/230806508.md) - [en](https://longbridge.com/en/news/230806508.md) - [zh-HK](https://longbridge.com/zh-HK/news/230806508.md) --- # Cookson Peirce & Co. Inc. Invests $975,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Cookson Peirce & Co. Inc. purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 11,670 shares of the biopharmaceutical company's stock, valued at approximately $975,000. - MarketBeat Week in Review – 01/13 - 01/17 A number of other institutional investors also recently made changes to their positions in ITCI. TimesSquare Capital Management LLC lifted its stake in shares of Intra-Cellular Therapies by 91.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company's stock worth $70,179,000 after acquiring an additional 402,186 shares during the period. Eagle Asset Management Inc. raised its holdings in shares of Intra-Cellular Therapies by 130.5% in the 3rd quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company's stock worth $45,714,000 after purchasing an additional 353,723 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock worth $129,463,000 after purchasing an additional 155,655 shares in the last quarter. Wasatch Advisors LP raised its holdings in shares of Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock worth $281,601,000 after purchasing an additional 130,351 shares in the last quarter. Finally, M&G PLC bought a new stake in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $9,076,000. 92.33% of the stock is owned by institutional investors and hedge funds. ## Intra-Cellular Therapies Stock Performance Shares of ITCI opened at $131.19 on Thursday. The company's 50 day moving average price is $117.36 and its 200 day moving average price is $92.79. Intra-Cellular Therapies, Inc. has a 52 week low of $63.30 and a 52 week high of $131.36. The company has a market capitalization of $13.95 billion, a PE ratio of -150.79 and a beta of 0.72. - Is Johnson & Johnson Stock Set to Reward Long-Term Holders? Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. On average, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year. ## Wall Street Analysts Forecast Growth A number of analysts recently commented on the stock. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their target price for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Tuesday. They issued a "hold" rating on the stock. Royal Bank of Canada restated a "sector perform" rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $106.08. - Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals **Get Our Latest Report on Intra-Cellular Therapies** ## Intra-Cellular Therapies Profile (Free Report) Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. ## Featured Articles - Five stocks we like better than Intra-Cellular Therapies - Technology Stocks Explained: Here's What to Know About Tech - Corporate Crawl: Where Business Trips Turn Into Party Nights - What is the Euro STOXX 50 Index? - CrowdStrike's Growth Remains Strong—Buy While It's Down - Trading Halts Explained - Is Advanced Micro Devices Stock Slide Over? _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Intra-Cellular Therapies Right Now? Before you consider Intra-Cellular Therapies, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list. While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ITCI.US](https://longbridge.com/en/quote/ITCI.US.md) ## Related News & Research - [13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc.](https://longbridge.com/en/news/296021707.md) - [Independent Financial Group LLC Purchases 57,994 Shares of Pfizer Inc. $PFE](https://longbridge.com/en/news/295997450.md) - [OS Therapies wins FDA Type C meeting to review 2.5-year survival data for OST-HER2 Phase 2b osteosarcoma trial](https://longbridge.com/en/news/295800970.md) - [OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates | OSTX Stock News](https://longbridge.com/en/news/296100226.md) - [293,524 Shares in GFL Environmental Inc. $GFL Bought by S&CO Inc.](https://longbridge.com/en/news/296021664.md)